UBS Group AG boosted its position in bluebird bio Inc (NASDAQ:BLUE) by 63.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 53,134 shares of the biotechnology company’s stock after purchasing an additional 20,723 shares during the period. UBS Group AG owned about 0.11% of bluebird bio worth $9,073,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the business. BlackRock Inc. boosted its position in bluebird bio by 1.0% in the first quarter. BlackRock Inc. now owns 3,868,157 shares of the biotechnology company’s stock worth $660,489,000 after purchasing an additional 36,786 shares during the last quarter. Franklin Resources Inc. boosted its position in bluebird bio by 41.3% in the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock worth $122,337,000 after purchasing an additional 200,900 shares during the last quarter. Northern Trust Corp boosted its position in bluebird bio by 0.4% in the first quarter. Northern Trust Corp now owns 592,198 shares of the biotechnology company’s stock worth $101,118,000 after purchasing an additional 2,644 shares during the last quarter. Two Sigma Advisers LP raised its stake in shares of bluebird bio by 3,004.0% in the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock worth $82,371,000 after buying an additional 447,600 shares during the period. Finally, Geode Capital Management LLC raised its stake in shares of bluebird bio by 9.0% in the fourth quarter. Geode Capital Management LLC now owns 454,997 shares of the biotechnology company’s stock worth $81,034,000 after buying an additional 37,588 shares during the period.
Shares of BLUE opened at $156.95 on Friday. bluebird bio Inc has a 12-month low of $85.65 and a 12-month high of $236.17.
bluebird bio (NASDAQ:BLUE) last issued its earnings results on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.01) by ($0.30). The business had revenue of $15.96 million for the quarter, compared to the consensus estimate of $5.85 million. bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm’s revenue for the quarter was up 133.7% compared to the same quarter last year. During the same period last year, the business posted ($1.68) EPS. research analysts anticipate that bluebird bio Inc will post -9.33 earnings per share for the current year.
In related news, insider David Davidson sold 22,000 shares of bluebird bio stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $167.52, for a total transaction of $3,685,440.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Vachon sold 6,000 shares of bluebird bio stock in a transaction that occurred on Monday, June 4th. The shares were sold at an average price of $188.22, for a total value of $1,129,320.00. Following the sale, the director now directly owns 3,000 shares in the company, valued at approximately $564,660. The disclosure for this sale can be found here. Insiders have sold a total of 65,401 shares of company stock worth $11,687,802 in the last three months. 3.00% of the stock is owned by corporate insiders.
Several research firms have recently commented on BLUE. BTIG Research raised their price objective on bluebird bio to $250.00 and gave the stock a “buy” rating in a research note on Thursday, March 8th. Janney Montgomery Scott began coverage on bluebird bio in a research note on Wednesday, March 14th. They issued a “neutral” rating and a $220.00 price objective on the stock. Canaccord Genuity reaffirmed a “buy” rating and issued a $250.00 price objective on shares of bluebird bio in a research note on Tuesday, March 13th. BidaskClub downgraded bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 16th. Finally, UBS Group began coverage on bluebird bio in a research note on Friday, March 16th. They issued a “sell” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $208.70.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.